AspCOVID-19 study: fungal infection of the airways in severe COVID-19 pneumonia

Invasive pulmonary aspergillosis in severe COVID-19 pneumonia: AspCOVID-19 study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN14810048

Enrollment

Registered

2020-11-17

Start date

2020-03-25

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) related pneumonia Infections and Infestations

Interventions

Screening of all mechanical ventilated patients with COVID-19 pneumonia for invasive pulmonary aspergillosis using the galactomannan from serum and broncho-alveolar lavage on day 1, 3, 7, 10, 14 and t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Critically ill patients with severe COVID-19 pneumonia

Exclusion criteria

Exclusion criteria: 1. Younger than 18 years old 2. Pregnancy 3. Missed informed consent

Design outcomes

Primary

Measure	Time frame
Pulmonary aspergillosis infection measured using the galactomannan from serum and broncho-alveolar lavage on day 1, 3, 7, 10, 14 and then every three days after ICU admission and intubation/mechanical ventilation	—

Secondary

Measure	Time frame
1. Duration of ICU stay measured using patient records 2. Mortality rate measured using patient records 3. Co-Infections measured using patient records 4. Ventilation time measured using patient records 5. Duration of hospital stay measured using patient records	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026